Latest News
Simbec-Orion and biotx.ai launch strategic partnership to de-risk early-stage drug development with AI supported clinical trial design.
26/10/2023
PRESS RELEASE: 26 October 2023 Simbec-Orion, a full-service mid-size CRO, and biotx.ai, a developer of AI-enabled causal modelling for drug development, have announced their strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design. Simbec-Orion, a specialist in oncology, rare disease, and clinical pharmacology studies, has over 45 years’ experience […]
Simbec-Orion Expands Immunoassay Capability
19/07/2023
In line with our continuing investment in technology, we have recently expanded our immunoassay capability with the addition of a second Ella™ ELISA analyser from ProteinSimple. Utilising Simple PlexTM technology, EllaTM is providing Simbec-Orion clients with access to an extensive library of key immunoassays to support the measurement of both the immunogenic potential and pharmacodynamic […]
Simbec-Orion to conduct a Phase II clinical trial in pulmonary sarcoidosis patients for Molecure’s OATD-01
18/07/2023
Warsaw, 3rd July 2023 Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program. Read the full press release here
Welcome to Simon Jennings
05/07/2023
We are delighted to share that Simon Jennings as joined Simbec-Orion as Vice President, Data Sciences. Simon has over 35 years in the pharmaceutical and CRO industry comprising a variety of global leadership roles in Biostatistics, Data Management, Statistical Programming and Biometrics Project Management covering all phases of clinical research in Glaxo, Celltech, Eisai, Sandoz/Novartis […]
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement
27/06/2023
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement ‹‹CIR – Crédit d’Impôt Recherche›› qui donne droit aux entreprises françaises qui sont assujetties à l’impôt sur les sociétés en France, la capacité de réclamer un allégement fiscal sur les coûts générés pour des activités concernant la Recherche & Développement externalisée par le […]
Steering Your Path to the Clinic, Complimentary Breakfast Workshop, June 29, Oxford UK
07/06/2023
How confident are you in your route to the clinic? There are multiple hurdles to be navigated, many of which can knock your development programme off course and threaten that all-important milestone. Optimising your clinical study design, so that it delivers the endpoints you need, without wasting time and budget, is crucial to keeping your […]
First Dose Administered in Phase I Trial of Novel Treatment for Cognitive Impairment Associated with Schizophrenia
09/03/2023
February 27, 2023 Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel treatment for cognitive impairment associated with schizophrenia and a range of disorders connected with the brain and central nervous system, has commenced in our MHRA Accredited Phase I Unit in South Wales. This is an […]
